TR200200441T2 - ATP bağlayıcı kaset transportör protein ABC1' i kullanarak kolesterolün dışa akımını artırmak ve HDL' yi yükseltmek için terkipler ve yöntemler. - Google Patents
ATP bağlayıcı kaset transportör protein ABC1' i kullanarak kolesterolün dışa akımını artırmak ve HDL' yi yükseltmek için terkipler ve yöntemler.Info
- Publication number
- TR200200441T2 TR200200441T2 TR2002/00441T TR200200441T TR200200441T2 TR 200200441 T2 TR200200441 T2 TR 200200441T2 TR 2002/00441 T TR2002/00441 T TR 2002/00441T TR 200200441 T TR200200441 T TR 200200441T TR 200200441 T2 TR200200441 T2 TR 200200441T2
- Authority
- TR
- Turkey
- Prior art keywords
- abc1
- methods
- increasing
- compositions
- cholesterol
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 235000012000 cholesterol Nutrition 0.000 title abstract 3
- 102000043966 ABC-type transporter activity proteins Human genes 0.000 title 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 title 1
- 101000800403 Arabidopsis thaliana UPF0051 protein ABCI8, chloroplastic Proteins 0.000 title 1
- 102100030488 HEAT repeat-containing protein 6 Human genes 0.000 abstract 8
- 101000990566 Homo sapiens HEAT repeat-containing protein 6 Proteins 0.000 abstract 8
- 101000801684 Homo sapiens Phospholipid-transporting ATPase ABCA1 Proteins 0.000 abstract 8
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
Abstract
Bu bulus, yeni ABC1 polipeptidleri ve bunlari kodlayan nükleik asit molekülleri, ayrica ABC1 polinükleotidlerini ihtiva eden rekombinant vektörler, konak hücreler ve terkipler, ve ABC1 polipeptidlerini meydana getirmeye mahsus yöntemlerle ilgilidir. Bu bulus ayrica, ABC1 polipeptidlerine spesifik olarak baglanan antikorlar, kolesterolün disa akimini artirmak için yöntemler yani sira ABC14 in ekspresyonunu ve aktivitesini artirmaya mahsus yöntemler, ABC1 in ekspresyonunu modüle eden bilesikleri teshis etmek için yöntemler ve bir memelide, ABC1 polipeptidleri ve polinükleotidlerinin nisbi seviyesini belirlemek için yötemlerle ilgilidir. Bu bulus ayrica, bilesiklerin ABC1 ekspresyonunu modüle etme aktivitesini belirlemek belirlemek için kitler ve terkipler yani sira, bir bilesigin, kolesterolün ABC1 e bagimli disa ayarlayip ayarlamadigini belirlemek için uygun kitler ve terkipler de saglar.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14026499P | 1999-06-18 | 1999-06-18 | |
| US15387299P | 1999-09-14 | 1999-09-14 | |
| US16657399P | 1999-11-19 | 1999-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200200441T2 true TR200200441T2 (tr) | 2002-11-21 |
Family
ID=27385472
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2002/00441T TR200200441T2 (tr) | 1999-06-18 | 2000-06-16 | ATP bağlayıcı kaset transportör protein ABC1' i kullanarak kolesterolün dışa akımını artırmak ve HDL' yi yükseltmek için terkipler ve yöntemler. |
| TR2002/00440T TR200200440T2 (tr) | 1999-06-18 | 2000-06-16 | ATP Bağlayıcı Kaset Transporter Protein ABC1'i kullanarak kolesterolün dışa akımını artırmak ve HDL'yi yükseltmek için terkipler ve yöntemler |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2002/00440T TR200200440T2 (tr) | 1999-06-18 | 2000-06-16 | ATP Bağlayıcı Kaset Transporter Protein ABC1'i kullanarak kolesterolün dışa akımını artırmak ve HDL'yi yükseltmek için terkipler ve yöntemler |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1190065A2 (tr) |
| JP (4) | JP2003508031A (tr) |
| KR (2) | KR100476519B1 (tr) |
| CN (2) | CN1379817A (tr) |
| AR (2) | AR024391A1 (tr) |
| AT (1) | ATE422545T1 (tr) |
| AU (3) | AU5743400A (tr) |
| BR (2) | BR0011753A (tr) |
| CA (2) | CA2375787C (tr) |
| DE (1) | DE60041545D1 (tr) |
| HK (2) | HK1046427A1 (tr) |
| IL (2) | IL147022A0 (tr) |
| MX (2) | MXPA01013174A (tr) |
| NO (2) | NO20016121L (tr) |
| NZ (3) | NZ516061A (tr) |
| SG (2) | SG121853A1 (tr) |
| TR (2) | TR200200441T2 (tr) |
| TW (2) | TWI304737B (tr) |
| WO (2) | WO2000078971A2 (tr) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617122B1 (en) | 1999-03-15 | 2003-09-09 | Xenon Genetics, Inc. | Process for identifying modulators of ABC1 activity |
| EP1854880A1 (en) * | 1999-03-15 | 2007-11-14 | University of British Columbia | Methods and reagents for modulating cholesterol levels |
| EP1212065A4 (en) * | 1999-07-08 | 2004-02-11 | Tularik Inc | COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL |
| EP1239848A2 (en) * | 1999-09-01 | 2002-09-18 | University of British Columbia | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| US6555323B2 (en) * | 2000-02-08 | 2003-04-29 | Pfizer Inc. | Assay for ABCA1 |
| WO2001083746A2 (en) | 2000-05-02 | 2001-11-08 | Aventis Pharma S.A. | Regulatory nucleic acid sequences of the abc1 gene |
| EP1203588A1 (en) * | 2000-11-06 | 2002-05-08 | Bayer Ag | Sterol-independent regulation of ABC1 promoter via oncostatinM |
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| AU2002317093A1 (en) * | 2001-07-03 | 2003-01-21 | University Of British Columbia | Screening processes for agents modulating cholesterol levels |
| CA2463395A1 (en) * | 2001-10-12 | 2003-04-24 | Grelan Pharmaceutical Co., Ltd. | Therapeutic agents for low hdl-cholesterolemia |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| EP1465882B1 (en) | 2001-12-21 | 2011-08-24 | X-Ceptor Therapeutics, Inc. | Hetrocyclic modulators of nuclear receptors |
| JP5082033B2 (ja) | 2001-12-21 | 2012-11-28 | エグゼリクシス パテント カンパニー エルエルシー | Ｌｘｒのモジュレーター |
| WO2004058717A1 (en) | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
| CA2532798C (en) | 2003-07-23 | 2013-02-19 | X-Ceptor Therapeutics Inc. | Azepine derivatives as pharmaceutical agents |
| WO2005116057A1 (en) * | 2004-05-27 | 2005-12-08 | Baker Medical Research Institute | Monoclonal antibody against abca1 |
| CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| PL2444424T3 (pl) | 2005-05-20 | 2019-01-31 | Ablynx N.V. | Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja |
| WO2007002559A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Pyrazole based lxr modulators |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| JP5227803B2 (ja) | 2006-11-24 | 2013-07-03 | ハイクス ラボラトリーズ合同会社 | スピロキノン化合物及び医薬組成物 |
| US9156914B2 (en) | 2006-12-19 | 2015-10-13 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| EP2115004A2 (en) | 2006-12-19 | 2009-11-11 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
| CA2706200A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Immunoglobulin constructs comprising multiple single variable domains and an fc portion |
| EP2247616A2 (en) | 2008-03-05 | 2010-11-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| US8557965B2 (en) | 2008-04-07 | 2013-10-15 | Ablynx N.V. | Single variable domains against notch pathway members |
| US10005830B2 (en) | 2009-03-05 | 2018-06-26 | Ablynx N.V. | Antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| DK2414521T3 (en) * | 2009-03-31 | 2017-01-30 | Massachusetts Gen Hospital | Regulation of miR-33 microRNAs in the treatment of cholesterol-related diseases |
| KR20130119990A (ko) | 2009-04-10 | 2013-11-01 | 아블린쓰 엔.브이. | Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드 |
| SI2435410T1 (sl) | 2009-05-28 | 2017-06-30 | Bristol-Myers Squibb Company | Lxr modulatorji |
| WO2011045079A1 (en) | 2009-10-15 | 2011-04-21 | Intercell Ag | Hepatitis b virus specific human antibodies |
| ES2723775T3 (es) | 2010-11-08 | 2019-09-02 | Ablynx Nv | Polipéptidos que se unen a CXCR2 |
| AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
| JP2014525736A (ja) | 2011-06-23 | 2014-10-02 | アブリンクス エン．ヴェー． | ＩｇＥに対する免疫グロブリン単一可変ドメイン |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| CA2876706A1 (en) | 2012-06-14 | 2013-12-19 | Ambrx, Inc. | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
| US9101745B2 (en) * | 2013-03-14 | 2015-08-11 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
| EP2967073B9 (en) | 2013-03-15 | 2019-04-10 | Bristol-Myers Squibb Company | Lxr modulators |
| US9834542B2 (en) | 2013-03-15 | 2017-12-05 | Bristo-Myers Squibb Company | LXR modulators |
| NL1040254C2 (en) | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| GB201315136D0 (en) * | 2013-08-23 | 2013-10-09 | Univ Glasgow | Cholesterol modulation |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| BR112018010802A2 (pt) | 2015-11-27 | 2018-11-27 | Ablynx Nv | polipeptídeos que inibem cd40l |
| WO2018050833A1 (en) | 2016-09-15 | 2018-03-22 | Ablynx Nv | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
| IL266506B2 (en) | 2016-11-16 | 2025-05-01 | Ablynx Nv | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
| US12129308B2 (en) | 2017-06-02 | 2024-10-29 | Merck Patent Gmbh | MMP13 binding immunoglobulins |
| EP3630818A1 (en) | 2017-06-02 | 2020-04-08 | Ablynx NV | Aggrecan binding immunoglobulins |
| KR102752550B1 (ko) | 2017-06-02 | 2025-01-10 | 메르크 파텐트 게엠베하 | Adamts 결합성 면역글로불린 |
| EP3630817A1 (en) | 2017-06-02 | 2020-04-08 | Merck Patent GmbH | Polypeptides binding adamts5, mmp13 and aggrecan |
| WO2021178974A1 (en) * | 2020-03-06 | 2021-09-10 | Endolytix Technology, Inc. | Compositions and methods for the treatment of intracellular bacterial infections |
| CN115433733B (zh) | 2021-06-04 | 2025-12-12 | 生物岛实验室 | 环状RNA Circ-ACE2翻译的多肽及其应用 |
| CN114369162B (zh) | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| CA3262070A1 (en) | 2022-07-14 | 2025-06-13 | Bio-Thera Solutions, Ltd. | ANTI-NECTIN-4 ANTIBODIES AND THEIR USES |
| TW202423965A (zh) | 2022-07-27 | 2024-06-16 | 比利時商艾伯霖克斯公司 | 與新生兒fc受體的特定表位結合之多肽 |
| TW202440614A (zh) | 2022-12-23 | 2024-10-16 | 比利時商艾伯霖克斯公司 | 基於蛋白質的接合載體 |
| CN120712282A (zh) | 2023-02-17 | 2025-09-26 | 阿布林克斯有限公司 | 结合新生儿fc受体的多肽 |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| TW202517676A (zh) | 2023-07-05 | 2025-05-01 | 比利時商艾伯霖克斯公司 | 用於治療ＩｇＧ相關疾病及病症之改良ＦｃＲｎ拮抗劑 |
| TW202525843A (zh) | 2023-09-04 | 2025-07-01 | 法商賽諾菲公司 | 用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽 |
| WO2025056575A1 (en) | 2023-09-11 | 2025-03-20 | Novo Nordisk A/S | Anti il-6 domain antibodies |
| WO2025061919A1 (en) | 2023-09-22 | 2025-03-27 | Ablynx Nv | Bi- and multivalent albumin binders |
| WO2025133166A1 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based carriers for site-specific amine conjugation |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| WO2025207946A1 (en) | 2024-03-28 | 2025-10-02 | Genzyme Corporation | Polypeptides binding to a specific epitope of the transferrin receptor 1 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001083746A2 (en) * | 2000-05-02 | 2001-11-08 | Aventis Pharma S.A. | Regulatory nucleic acid sequences of the abc1 gene |
-
2000
- 2000-06-16 AT AT00942914T patent/ATE422545T1/de not_active IP Right Cessation
- 2000-06-16 CN CN00809163A patent/CN1379817A/zh active Pending
- 2000-06-16 CN CNB008091641A patent/CN100513570C/zh not_active Expired - Fee Related
- 2000-06-16 NZ NZ516061A patent/NZ516061A/en unknown
- 2000-06-16 NZ NZ531401A patent/NZ531401A/en unknown
- 2000-06-16 WO PCT/US2000/016591 patent/WO2000078971A2/en not_active Ceased
- 2000-06-16 JP JP2001515880A patent/JP2003508031A/ja active Pending
- 2000-06-16 WO PCT/US2000/016765 patent/WO2000078972A2/en not_active Ceased
- 2000-06-16 EP EP00942867A patent/EP1190065A2/en not_active Withdrawn
- 2000-06-16 NZ NZ529785A patent/NZ529785A/en unknown
- 2000-06-16 HK HK02107131.3A patent/HK1046427A1/zh unknown
- 2000-06-16 TR TR2002/00441T patent/TR200200441T2/tr unknown
- 2000-06-16 CA CA002375787A patent/CA2375787C/en not_active Expired - Fee Related
- 2000-06-16 SG SG200307656A patent/SG121853A1/en unknown
- 2000-06-16 MX MXPA01013174A patent/MXPA01013174A/es unknown
- 2000-06-16 BR BR0011753-6A patent/BR0011753A/pt not_active Application Discontinuation
- 2000-06-16 AU AU57434/00A patent/AU5743400A/en not_active Abandoned
- 2000-06-16 IL IL14702200A patent/IL147022A0/xx unknown
- 2000-06-16 SG SG200307655A patent/SG121852A1/en unknown
- 2000-06-16 DE DE60041545T patent/DE60041545D1/de not_active Expired - Fee Related
- 2000-06-16 HK HK02108234.7A patent/HK1046708A1/zh unknown
- 2000-06-16 CA CA002375781A patent/CA2375781A1/en not_active Abandoned
- 2000-06-16 KR KR10-2001-7016284A patent/KR100476519B1/ko not_active Expired - Fee Related
- 2000-06-16 JP JP2001515881A patent/JP2003506097A/ja active Pending
- 2000-06-16 AU AU57467/00A patent/AU777461B2/en not_active Ceased
- 2000-06-16 EP EP00942914A patent/EP1218515B1/en not_active Expired - Lifetime
- 2000-06-16 MX MXPA01013175A patent/MXPA01013175A/es active IP Right Grant
- 2000-06-16 IL IL14702100A patent/IL147021A0/xx unknown
- 2000-06-16 AR ARP000103012A patent/AR024391A1/es unknown
- 2000-06-16 BR BR0011696-3A patent/BR0011696A/pt not_active IP Right Cessation
- 2000-06-16 KR KR1020017016286A patent/KR20020012612A/ko not_active Ceased
- 2000-06-16 AR ARP000103013A patent/AR024576A1/es unknown
- 2000-06-16 TR TR2002/00440T patent/TR200200440T2/tr unknown
- 2000-08-25 TW TW095113205A patent/TWI304737B/zh active
- 2000-08-25 TW TW089111924A patent/TWI259205B/zh not_active IP Right Cessation
-
2001
- 2001-12-14 NO NO20016121A patent/NO20016121L/no not_active Application Discontinuation
- 2001-12-14 NO NO20016114A patent/NO20016114L/no unknown
-
2004
- 2004-11-04 JP JP2004320358A patent/JP4277956B2/ja not_active Expired - Fee Related
-
2005
- 2005-01-14 AU AU2005200171A patent/AU2005200171A1/en not_active Abandoned
- 2005-10-26 JP JP2005311515A patent/JP2006137750A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200200441T2 (tr) | ATP bağlayıcı kaset transportör protein ABC1' i kullanarak kolesterolün dışa akımını artırmak ve HDL' yi yükseltmek için terkipler ve yöntemler. | |
| Kerlavage et al. | Covalent modification of an adenosine 3': 5'-monophosphate binding site of the regulatory subunit of cAMP-dependent protein kinase II with 8-azidoadenosine 3': 5'-monophosphate. Identification of a single modified tyrosine residue. | |
| Thelander | Physicochemical characterization of ribonucleoside diphosphate reductase from Escherichia coli | |
| Sebastiano et al. | A new deuterated alkylating agent for quantitative proteomics | |
| CA2413857A1 (en) | Pd-l2 molecules: pd-1 ligands and uses therefor | |
| ATE549347T1 (de) | Gene von säugetiere, und damit verbundene reagentien, methoden | |
| DE69840669D1 (de) | Pca3, pca3-gene und verfahren zu ihrer verwendung | |
| DK0930366T3 (da) | Bindingsdomæner i Delta-proteiner | |
| NZ323795A (en) | Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides | |
| BR9712298A (pt) | Polipeptìdeo, molécula de dna, vetor de expressão recombinante, célula hospedeira, processo para detectar infecção por m. tuberculosis em uma amostra biológica, kit diagnóstico, anticorpos monoclonal, e, policlonal, e, proteìna de fusão | |
| Mende et al. | Automated Fmoc-based solid-phase synthesis of peptide thioesters with self-purification effect and application in the construction of immobilized SH3 domains | |
| AU3618095A (en) | Alk-7 (activin like kinase), a serine threonine kinase receptor | |
| HUP0100668A2 (hu) | Virulenciával kapcsolatos nukleinsavszekvenciák és alkalmazásuk | |
| Grammer et al. | Chemistry and mechanism of vanadate-promoted photooxidative cleavage of myosin | |
| Mole | A genetic marker in the variable region of rabbit immunoglobulin heavy chain | |
| SE9801148D0 (sv) | New receptors | |
| WO2003008626A3 (en) | Novel human nucleic acids encoding a pantothenate kinase and methods of use | |
| Xiang et al. | Elution-modified displacement chromatography coupled with electrospray ionization-MS: on-line detection of trace peptides at low-femtomole level in peptide digests | |
| Sun et al. | Mass spectrometric characterization of mitochondrial electron transport complexes: subunits of the rat heart ubiquinol–cytochrome c reductase | |
| Allen | Applications of polyacrylamide gel electrophoresis and polyacrylamide gel isoelectric focusing in clinical chemistry | |
| Lahue et al. | The influence of quaternary structure on the active site of an oligomeric enzyme. Catalytic subunit of aspartate transcarbamoylase. | |
| Pflug | Subtyping of group specific component (GC) in microbloodstains and semen stains by isoelectric focusing in ultrathin immobilized pH gradient gels followed by enzyme immunodetection | |
| Iida et al. | Identification of novel fibronectin fragments detected specifically in juvenile urine | |
| EA200300420A1 (ru) | Выделенная молекула нуклеиновой кислоты, выделенный полипептид и способ его получения, способ обнаружения их присутствия в образце (варианты), клетка-хозяин (варианты), антитело, набор (варианты), способ модулирования активности полипептида, способ идентификации (варианты) и применение соединения, способ выявления субъекта (варианты) и способ лечения субъекта с нарушением, связанным с калиевыми каналами (варианты) | |
| Awada et al. | Affinity-trap polyacrylamide gel electrophoresis: A novel method of capturing specific proteins by electro-transfer |